Jacobs Levy Equity Management
AKRO

Jacobs Levy Equity Management’s Akero Therapeutics AKRO Stock Holding History

Jacobs Levy Equity Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-56,533
Closed -$1.74M – 1009
2020
Q3 		$1.74M Sell
56,533
-7,943
-12% -$278K 0.02% 543
2020
Q2 		$1.61M Buy
+64,476
New +$1.47M 0.02% 566

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jacobs Levy Equity Management's AKRO Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Akero Therapeutics (AKRO) in Q4 2020, closing a stake of 56,533 shares — an estimated $1.74M sold.

Jacobs Levy Equity Management first reported a position in AKRO in Q2 2020 and held it in 2 quarters. The position peaked at $1.74M in Q3 2020. 94 funds tracked by Wall St. Rank hold AKRO as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining Akero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 56,533 Akero Therapeutics shares in Q4 2020, an estimated $1.74M.
  • Jacobs Levy Equity Management first reported a position in Akero Therapeutics in Q2 2020 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Akero Therapeutics position peaked at $1.74M in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.